CSPC Pharmaceutical Group Limited (CSPC Pharma) has obtained drug-registration approval from China’s National Medical Products Administration (NMPA) for its Aprepitant Injection (4.4 ml:32 mg), a submicron emulsion formulation of the neurokinin-1 (NK-1) receptor antagonist aprepitant.

The newly approved product is indicated for the prevention of post-operative nausea and vomiting (PONV) in adults. According to the company, the submicron emulsion offers a faster onset of action, improves patient compliance and lowers the incidence of allergic reactions compared with traditional aprepitant formulations, potentially enhancing clinical outcomes in surgical aftercare.

This approval follows the September 2024 clearance of CSPC Pharma’s Aprepitant Injection (18 ml:130 mg), which is used to prevent chemotherapy-induced nausea and vomiting. The addition of the 32 mg dosage form broadens the company’s antiemetic portfolio and strengthens its competitive position in this therapeutic segment.

The announcement was issued by CSPC Pharma’s board on 23 March 2026. Chairman: Cai Dong Chen.